![silvadene cream silvadene cream](https://img.medscapestatic.com/pi/features/drugdirectory/octupdate/PFZ01311.jpg)
Findings demonstrated that the use of SilvaSorb Gel was associated with less pain and greater patient satisfaction when compared with Silvadene. A total of 24 patients were enrolled and completed the study. Inclusion criteria were patients ranging in age from 2 months to 18 years with TBSA ranging from 1 up to 40%.
Silvadene cream full#
Pediatric patients were randomly assigned to treatment with either SilvaSorb Gel (Medline Industries, Munedelein, IL) or Silvadene silver sulfadiazine cream (King Pharmaceuticals, Bristol, TN) for up to 21 days or to the point of full reepithelialization of the wound. If a breast-feeding infant experiences an adverse effect related to a maternally ingested drug, healthcare providers are encouraged to report the adverse effect to the FDA.This prospective, randomized study assessed the clinical, microbiological, and patient comfort characteristics of two silver-based topical agents in the management of partial-thickness burn wounds. Consider the benefits of breast-feeding, the risk of potential infant drug exposure, and the risk of an untreated or inadequately treated condition. However, sulfonamides are known to be excreted in human milk, and all sulfonamide derivatives are known to increase the possibility of kernicterus. It is not known whether it is excreted in human milk. Nevertheless, sulfonamides should be used with caution during near term pregnancy because of the potential risk of causing kernicterus in newborns.Īccording to the manufacturer, because of the possibility for serious adverse reactions in nursing infants from sulfonamides, silver sulfadiazine should not be used during breast-feeding. Since silver sulfadiazine is administered topically, it seems even less likely than systemically administered sulfonamides to invoke this adverse reaction. While this adverse reaction has occurred when a sulfonamide was administered directly to the newborn, it has not been demonstrated in a newborn when exposed to the drug in utero. Sulfonamides can displace bilirubin from protein binding sites and theoretically precipitate kernicterus in newborns. According to the manufacturer, it is contraindicated in near-term pregnancy because sulfonamides may promote kernicterus in the newborn by displacing bilirubin from plasma proteins. Silver sulfadiazine is classified in FDA pregnancy category B. Sulfacetamide sodium should not be applied to the same sites as products containing silver salts, including preparations such as silver nitrate, silver sulfadiazine, or mild silver protein.
![silvadene cream silvadene cream](http://img.medscapestatic.com/pi/features/drugdirectory/octupdate/MON01310.jpg)
Sulfacetamide Sulfur: (Major) Topical and ophthalmic sulfonamides are incompatible with preparations containing silver. Sulfacetamide: (Major) Topical and ophthalmic sulfonamides are incompatible with preparations containing silver. In vitro data suggest silver may decrease the viability of keratinocytes and human dermal fibroblasts. Administering these drugs together may reduce wound repair and regeneration. Keratinocytes Fibroblasts Collagen: (Major) Avoid the use of silver-containing antimicrobials or dressing (such as silver sulfadiazine) in patients receiving treatment with keratinocytes and dermal fibroblast collagen. Collagenase: (Contraindicated) Silver sulfadiazine should not be used with the proteolytic enzymes collagenase, papain, or sutilains because heavy metals such as silver inactivate these enzymes.